Navigation Links
New study finds no benefit to selecting dose of blood thinner based on patients' genetic makeup
Date:11/19/2013

DALLAS A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has determined that a gene-based method for selecting patients' doses of the popular heart medication warfarin is no better than standardized dosing methods. The study was presented today at the 2013 Scientific Sessions of the American Heart Association and published simultaneously in the New England Journal of Medicine.

"There has been much interest in the medical community about the utility of pharmacogenetics using information about a person's genetic makeup to choose the drugs and drug doses that are most likely to work well for that particular person to help better personalize treatments for patients and improve drug safety and efficacy," said lead study author Stephen Kimmel, MD, MSCE, professor of Medicine and Epidemiology at Penn Medicine. "Warfarin therapy has served as a model for the promise of a gene-based approach to patient care, but we needed a large, prospective clinical trial to determine if a patient's genetic information provides the added benefit above and beyond what can be obtained simply with clinical information."

Warfarin is a blood thinner used to prevent clots and is generally considered to be a very effective medication, but dosing must be properly adjusted for each patient, who are closely monitored for complications. Approximately 2 million Americans, primarily older patients, take warfarin to keep blood from excessive clotting, or coagulation. Currently, doctors face major challenges in determining the right dose of warfarin for each patient because individuals vary widely in how quickly their bodies' break down and respond to the drug. Taking too much warfarin could result in bleeding problems and taking too little warfarin will not stop clots from forming.

Previous research has shown that two genes, CYP2C9 and VKORC1, which vary among different individuals, can influence warfarin's effectiveness. In 2007 and 2010, the FDA worked with the makers of warfarin drug products to modify the product label to indicate that a patient's genetic makeup may affect how he or she responds to the drug and that genetic information might be useful in determining the optimal starting dose.

To find out whether these genes could help clinicians prescribe an optimal dose, the Clarification of Optimal Anticoagulation through Genetics (COAG) trial consisting of 18 clinical sites across the country and funded by the National Heart, Lung and Blood Institute (NHLBI) tested two approaches for determining the best initial dose of warfarin in patients who were expected to need therapy for at least one month or longer by clinical information alone or by clinical information plus specific genetic information. The four-year study included 1,015 patients randomly assigned to one of two groups during the first five days of initiating warfarin therapy.

For the patients in the clinical-based dosing group, the initial warfarin dose was determined using step-by-step procedures based only on information about clinical factors, such as age, sex, weight, ethnicity, and the use of other medications. In the gene-based dosing group, the initial dose was determined using this same clinical information as well as information about the patient's genetic makeup, including analyzing the participants' DNA for the CYP2C9 and VKORC1 genes. Patients and their providers were blinded to the dose of warfarin for the first month of therapy.

The researchers found that there was no difference among the two groups in mean percentage of time in therapeutic range (PTTR) for the medication (45.2 percent in the pharmacogenetic-dosing group versus 45.4 percent in the clinical-guided dosing group) at four-weeks. There was, however, a statistically significant difference by race. Among African Americans, the mean PTTR for the pharmacogenetic-guided dosing group was less than that for the clinical-guided dosing group 35.2 percent versus 43.5 percent, respectively. Pharmacogenetic-based dosing also led to more over-anticoagulation and a longer time to first therapeutic levels of the warfarin among African Americans.

The authors note that despite the positive results from other smaller studies analyzing the benefits of gene-based prescribing therapy, the results of this trial do not support the hypothesis that initiating warfarin therapy at a pharmacogenetic-predicted maintenance dose improves anticoagulation control over clinical methods. They point out that previous studies were primarily conducted at single clinical sites, were not blinded, and involved a limited number participants. They conclude that the COAG trial emphasizes the importance of performing large randomized trials for additional pharmacogenetics approaches, particularly for complex medicine regimens such as warfarin.


'/>"/>

Contact: Jessica Mikulski
jessica.mikulski@uphs.upenn.edu
215-796-4829
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. New study reports on the high cost of cardiac surgery healthcare associated infections
2. New Study May Impact Practice Guidelines for Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation
3. Study may impact guidelines for mitral valve surgery for severe ischemic mitral regurgitation
4. Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows
5. Chicago man breathes again thanks to Northwestern Medicine study
6. Study finds youth prefer and benefit more from rapid point-of-care HIV testing
7. Study: Ureteral injury during robot-assisted prostate surgery
8. Study: Odds of rehospitalization of cognitively impaired varies by discharge destination
9. A CNIO study recreates the history of life through the genome
10. Dr. Joe Dentistry Promotes Dental Exams as New Study Links Heart Disease to Oral Health
11. Study questions hypothermia treatment for cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
Breaking Medicine Technology: